EMBER-2 (J2J-MC-JZLB)

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Ouvert à Saint-Cloud depuis le : 22/04/2021
Public cible : Adult
Phase : Phase I

Description de l'essai

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

Url of the trial

Investigateur principal

FRANCOIS-CLEMENT BIDARD

Professeur - Médecin

Contacter